By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Cubist Pharmaceuticals, Inc. 

65 Hayden Avenue

Lexington  Massachusetts  02421  U.S.A.
Phone: 781-860-8660 Fax: 781-861-0566


SEARCH JOBS
There’s something special about working at Cubist Pharmaceuticals.

We provide a progressive, flexible work environment and a highly competitive total rewards program designed to meet your work/life needs now and in the future. In our product, our pipeline and in our supportive culture, Cubist demonstrates its continuing commitment of excellence to our employees and our shareholders.

Cubist is a bio-pharmaceutical company focused on the research, commercial¬ization and creation of pharmaceutical products that address unmet medical needs in the acute care environment. CUBICIN® , (daptomycin for injection), our marketed product, has been used in the treatment of more than an estimated 1.1 million patients with serious and sometimes life-threatening infections. CUBICIN has generated hundreds of millions of dollars in annual sales that helped propel Cubist into one of the Commonwealth's best-performing firms as evidenced by recent recognition. Cubist was ranked among Top Pharmas on the Scrip 100 List, while Forbes recently listed Cubist as one of 14 "Productivity Powerhouses." Cubist appeared in The Boston Globe's 2010 annual list of the "Top Places to Work" in Massachusetts (for the third consecutive year).

Mass High Tech announced that Cubist ranked 13th among the top 30 Fastest-Growing Public Technology Companies in New England for 2010 and was one of only ten pharmaceutical companies to make that list. Cubist also debuted as the 31st overall company and top pharmaceutical company named to FORTUNE's 2010 List of 100 Fastest-Growing Companies, and was named to the 2010 Deloitte Technology Fast 500™ for the sixth consecutive year.


Key Statistics


Email: ir@cubist.com
Ownership: Public

Web Site: Cubist Pharmaceuticals, Inc.
Employees: ~600
Symbol: CBST
 









Company News
Cubist Pharmaceuticals, Inc. (CBST) Opens Global HQ; To Invest Approximately $400 Million On Antibiotic R&D 9/18/2014 9:14:26 AM
Cubist Pharmaceuticals, Inc. (CBST) To Present At Morgan Stanley Global Healthcare Conference 8/25/2014 9:23:33 AM
Cubist Pharmaceuticals, Inc. (CBST) Announces European Medicines Agency Acceptance Of Ceftolozane/Tazobactam Marketing Authorization Application For Review 8/22/2014 10:49:38 AM
Cubist Pharmaceuticals, Inc. (CBST) Could Be An Acquisition Target For Needy Pfizer Inc. (PFE) 8/18/2014 9:51:07 AM
Cubist Pharmaceuticals, Inc. (CBST) Issues Voluntary Nationwide Recall Of Nine Lots Of CUBICIN (Daptomycin For Injection) 500 Mg In 10 Ml Single Use Vials Following Complaints Of Foreign Particulate Matter In Reconstituted Vials 8/11/2014 8:45:54 AM
Cubist Pharmaceuticals, Inc. (CBST) Recalls Some Vials Of Antibiotic Cubicin 8/6/2014 6:37:29 AM
Cubist Pharmaceuticals, Inc. (CBST)’s Once-Daily SIVEXTRO™ (Tedizolid Phosphate) Available For Physician And Hospital Order In I.V. And Oral Formulations 8/5/2014 8:45:58 AM
Cubist Pharmaceuticals, Inc. (CBST) To Present At August Investor Conference 7/28/2014 8:46:31 AM
Cubist Pharmaceuticals, Inc. (CBST) Strikes Agreement With Competitor To Delay Generic Cubicin 7/24/2014 7:04:19 AM
Cubist Pharmaceuticals, Inc. (CBST) Reports Second Quarter 2014 Financial Results 7/23/2014 4:55:15 PM
12345678910...
//-->